Publications by authors named "Nonhlanhla N Mkhize"

Claim this Profile
P
Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapy.
Lutz Gieselmann, Andrew T DeLaitsch, Malena Rohde, Henning Gruell, Christoph Kreer, Nonhlanhla N Mkhize

Nat Immunol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contemporary HIV-1 envelope pseudovirus panels for detecting and assessing B cell lineages with broadly neutralizing antibody potential.
Bette Korber, Michael S Seaman, Nonhlanhla N Mkhize, Kelli Greene, Hongmei Gao

bioRxiv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasmodium falciparum Parasitemia Does Not Diminish Neutralizing Antibody Responses After mRNA COVID-19 Booster Vaccination in HIV-infected Adults.
Taraz Samandari, Millicent Achola, Jack N Hutter, Grace Mboya, Walter Otieno, Nonhlanhla N Mkhize

J Infect Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV.
Nonhlanhla N Mkhize, Bo Zhang, Caroline Brackett, Peter James Elyanu, Asa Tapley

Nat Commun· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VRC01 Selects Rare HIV Escape Mutations After Acquisition in Antibody-Mediated Prevention Trials.
Carolyn Williamson, Lyle Curry, Nonhlanhla N Mkhize, Elena E Giorgi, Craig A Magaret

bioRxiv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutralizing antibody responses over time in a demographically and clinically diverse cohort of individuals recovered from SARS-CoV-2 acquisition in Africa: A cohort study.
Nonhlanhla N Mkhize, Shuying Sue Li, Jiani Hu, Samuel T Robinson, Zaheer Hoosain

PLOS Glob Public Health· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid loss of activity but not serum concentration in a passive infusion clinical trial of an HIV neutralizing antibody.
Sharana Mahomed, Nonhlanhla N Mkhize, Leonid A Serebryannyy, Tandile Hermanus, Prudence Kgagudi

medRxiv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Profiling a large HIV-1 elite neutralizer cohort reveals remarkable CD4bs bNAb for HIV-1 prevention and therapy.
Lutz Gieselmann, Andrew T DeLaitsch, Malena Rohde, Henning Gruell, Christoph Kreer, Nonhlanhla N Mkhize

bioRxiv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials.
Carolyn Williamson, Chivonne Moodley, Craig A Magaret, Elena E Giorgi, Morgane Rolland, Nonhlanhla N Mkhize

bioRxiv· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRAVE: a highly accurate method for predicting HIV-1 antibody resistance using large language models for proteins.
Mohammed El Anbari, Tatsiana Bylund, Sijy O'Dell, Emily Tourtellott, Krisha McKee, Nonhlanhla N Mkhize

bioRxiv· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and implementation of phase I randomized GLA-SE-adjuvanted CH505TF gp120 HIV vaccine trial in newborns.
Avy Violari, Kennedy Otwombe, William Hahn, Shiyu Chen, Deirdre Josipovic, Nonhlanhla N Mkhize

J Clin Invest· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct region-specific neutralization profiles of contemporary HIV-1 clade C against best-in-class broadly neutralizing antibodies.
Jyoti Sutar, Priyanka Jayal, Ranajoy Mullick, Sangeeta Chaudhary, Prajakta Kamble, Nonhlanhla N Mkhize

J Virol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial.
Kelly E Seaton, Carmen A Paez, Chenchen Yu, Shelly T Karuna, Theresa Gamble, Nonhlanhla N Mkhize

Lancet HIV· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective analysis of sex-disaggregated immune responses to ALVAC-HIV and bivalent subtype C gp120/MF59 HIV vaccines.
Cassie G Ackerley, Srilatha Edupuganti, Chenchen Yu, Alison C Roxby, Kelly E Seaton, Nonhlanhla N Mkhize

Front Immunol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutralizing Antibody Responses After mRNA COVID-19 Booster Vaccination are Unaffected by Parasitemia in a Malaria-Endemic Setting.
Taraz Samandari, Millicent Achola, Jack N Hutter, Grace Mboya, Walter Otieno, Nonhlanhla N Mkhize

medRxiv· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance.
Paula Cohen, Bronwen E Lambson, Nonhlanhla N Mkhize, Chivonne Moodley, Anna E J Yssel

J Virol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and implementation of a phase 1 randomized GLA-SE-adjuvanted CH505TF gp120 HIV vaccine trial in newborns.
Avy Violari, Kennedy Otwombe, William Hahn, Shiyu Chen, Deirdre Josipovic, Nonhlanhla N Mkhize

medRxiv· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial.
Vimla Naicker, Fatima Laher, Linda-Gail Bekker, Kelly E Seaton, Mary Allen, Nonhlanhla N Mkhize

PLOS Glob Public Health· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and pharmacokinetics of subcutaneous administration of broadly neutralizing anti-HIV-1 monoclonal antibodies (bNAbs), given to HIV-1 exposed, uninfected neonates and infants: study protocol for a phase I trial.
Ameena Goga, Trisha Ramraj, Logashvari Naidoo, Brodie Daniels, Masefetsane Matlou, Nonhlanhla N Mkhize

BMC Infect Dis· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials.
Daniel B Reeves, Bryan T Mayer, Allan C deCamp, Yunda Huang, Bo Zhang, Nonhlanhla N Mkhize

Nat Commun· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials.
Daniel B Reeves, Bryan T Mayer, Allan C deCamp, Yunda Huang, Bo Zhang, Nonhlanhla N Mkhize

Nat Commun· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infection pre-Ad26.COV2.S-vaccination primes greater class switching and reduced CXCR5 expression by SARS-CoV-2-specific memory B cells.
Robert G E Krause, Thandeka Moyo-Gwete, Simone I Richardson, Zanele Makhado, Nelia P Manamela, Nonhlanhla N Mkhize

NPJ Vaccines· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials.
Nonhlanhla N Mkhize, Anna E J Yssel, Haajira Kaldine, Rebecca T van Dorsten, Amanda S Woodward Davis

PLoS Pathog· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial.
Sharana Mahomed, Nigel Garrett, Edmund V Capparelli, Farzana Osman, Nonhlanhla N Mkhize

Lancet HIV· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition.
Peter B Gilbert, Yunda Huang, Allan C deCamp, Shelly Karuna, Yuanyuan Zhang, Nonhlanhla N Mkhize

Nat Med· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis